Skip to main content
Impact of insurance status on MRI phenotypes in MS.
Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab.
Assessment of dietary intake and its inflammatory potential in persons with pediatric-onset multiple sclerosis.
Gene-environment interactions and risk of pediatric-onset multiple sclerosis associated with time spent outdoors.
High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases.
Silent findings: Examination of asymptomatic demyelination in a pediatric US cohort.
Stroke Outcomes and Hyperacute Treatment Utilization in Multiple Sclerosis.
High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics.
Ethical considerations in the treatment of multiple sclerosis fatigue.
Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion.